Bret Jensen

|RSS

Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

By

Bret Jensen

 | Apr 27, 2017 | 12:04 PM EDT
It's a mixed market as we head to the noon hour ET. Nasdaq is the only major index in the green, while everything else is sporting mild losses. Not…
By

Bret Jensen

 | Apr 27, 2017 | 10:09 AM EDT
The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb…
RMPIA
By

Bret Jensen

 | Apr 27, 2017 | 8:49 AM EDT
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today.…
RMPIA
By

Bret Jensen

 | Apr 27, 2017 | 7:23 AM EDT
As always, it is good to be sitting in for Doug Kass on the Daily Diary over the next two days. There is lots to talk about. We have a flood of…
RMPIA
By

Bret Jensen

 | Apr 26, 2017 | 11:30 AM EDT
Biotech investors should keep a close eye on the progress in this huge potential market.
By

Bret Jensen

 | Apr 24, 2017 | 11:30 AM EDT
Three small-cap biotechs with attractive risk/reward profiles.
RMPIA
By

Bret Jensen

 | Apr 21, 2017 | 11:30 AM EDT
They have faster growth prospects and sell for slightly cheaper valuations, as well.
RMPIA
By

Bret Jensen

 | Apr 19, 2017 | 11:30 AM EDT
Choosing what sectors to underweight is as important as choosing what stocks to place in your portfolio.
RMPIA
By

Bret Jensen

 | Apr 17, 2017 | 12:30 PM EDT
Forget financials, stick to steady growers.
By

Bret Jensen

 | Apr 12, 2017 | 11:00 AM EDT
Acadia and Neurocrine both have catalysts for growth; buy any weakness.

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.